COMPANY

Pelthos Therapeutics

HQ: Durham, NC source · pelthos.com ↗ · Southeast

8 open jobs · last seen Oct 23, 2026 · 1 source

Deal: Pelthos acquired Xepi® (ozenoxacin) Cream, 1% a topical treatment for impetigo and Xeglyze® (abametapir) topical treatment for head lice from an unnamed seller · Asset/program acquisition · 4th Quarter of 2025 · source

Location: Durham, NC · source · Oct 14, 2026

Profile checked Oct 10, 2026

8Open jobs

Hiring

Title	Location (from posting)	Employer posted	First seen
Territory Manager, Philadelphia, PA	Philadelphia, Pennsylvania, United States	Not stated	Oct 23, 2026
Director, Regulatory Affairs	Durham, North Carolina	Not stated	Oct 11, 2026
Territory Manager, Santa Ana, CA	Santa Ana, California, United States	Not stated	Oct 11, 2026
Territory Manager, Las Vegas, NV	Las Vegas, Nevada, United States	Not stated	Oct 11, 2026
Territory Manager, Salt Lake City, UT	Salt Lake City, Utah, United States	Not stated	Oct 11, 2026

See all 8 jobs

Funding and NIH signals

SEC Form D raise Raised $18M (Form D filed Nov 19, 2025); 12 roles open. SEC Form D 0001919246-25-000006 (Nov 19, 2025)
Evidence (1 event)
- Nov 19, 2025 · SEC Form D 0001919246-25-000006
  Name of Issuer: Pelthos Therapeutics Inc.; CIK: 1919246; Address: Durham, NC; Submission type: D; Filing date: 2025-11-19; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-06; Types of Securities Offered: Option/warrant, Security to be acquired, Other (Senior secured convertible notes, which are convertible into shares of the Company's common stock, par value $0.0001 per share.); Business combination transaction: false; Total Offering Amount: 18000000; Total Amount Sold: 18000000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jan 13, 2026 Debt Debt financing: $50M (up to, as announced), announced Jan 13, 2026. Source: SEC filing. source ↗

Funding

Debt: $50.0M. Last 2 years.

Jan 13, 2026 Debt financing: $50M (up to, as announced), announced Jan 13, 2026. Source: SEC filing. source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2025-11-19 Raise Private raise (SEC Form D): $18.0M sold; issuer “Pelthos Therapeutics Inc.”. Verified from the SEC filing. SEC filing ↗
2025-07-10 Raise Private raise (SEC Form D): $50.1M sold; issuer “Pelthos Therapeutics Inc.”. Verified from the SEC filing. SEC filing ↗

Open jobs 8

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Territory Manager, Philadelphia, PA	Philadelphia, Pennsylvania, United States	Not stated	Oct 23, 2026	Not stated
Director, Regulatory Affairs	Durham, North Carolina	Not stated	Oct 11, 2026	Senior
Territory Manager, Santa Ana, CA	Santa Ana, California, United States	Not stated	Oct 11, 2026	Mid
Territory Manager, Las Vegas, NV	Las Vegas, Nevada, United States	Not stated	Oct 11, 2026	Mid
Territory Manager, Salt Lake City, UT	Salt Lake City, Utah, United States	Not stated	Oct 11, 2026	Mid
Territory Manager, Nashville, TN	Nashville, Tennessee, United States	Not stated	Oct 11, 2026	Mid
Territory Manager, Indianapolis, IN	Indianapolis, Indiana, United States	Not stated	Oct 11, 2026	Mid
Territory Manager, Boston, MA	Boston, Massachusetts, United States	Not stated	Oct 11, 2026	Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Pelthos Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18